期刊文献+

伊布利特在持续性心房颤动射频消融术中转律的疗效特点 被引量:7

Efficacy of ibutilide for cardioversion of persistent atrial fibrillation during radiofrequency ablation
原文传递
导出
摘要 目的评价伊布利特在持续性心房颤动(房颤)射频消融术中应用的有效性及影响因素。方法人选接受射频消融手术的持续性房颤患者18例,男性16例,女性2例,平均年龄(56.3±14.0)岁,体质量(81.22±8.93)kg,合并原发性高血压3例、肥厚型心肌病2例。所有患者术中经环肺静脉电隔离、线性消融、碎裂电位消融后房颤未终止,或者转为心房扑动,给予伊布利特1mg、10min内静脉注射,观察开始给药后30min内的转复率及4h内的不良反应。根据用药后是否成功转律分为转律组与非转律组。结果(1)18例患者用药后30min内成功转律11例,转复律为61.11%,平均转律时间为(13.80±7.64)min,转复剂量为(0.94±0.13)mg。1例患者用药后15rain时出现窦性停搏16s,后恢复稳定窦性心律,术后观察4h无不良反应,另1例患者用药后出现窦性心动过缓,持续约1h后恢复正常心率,期间无低血压等血流动力学改变。余16例患者术中及术后4h内无室性心动过速及低血压等不良反应。(2)使用伊布利特后30min的AA间期(0.51±0.08)s,明显长于用药前的AA间期(0.39±0.21)s,P〈0.01;用药后30min的QTc(0.51±0.08)s,明显长于用药前QTc(0.39±0.21)s,P〈0.01。(3)两组临床资料差异无统计学意义。转律组患者左房瘢痕区比例(5.12±3.83)%,明显小于非转律组左房瘢痕区比例(12.40±11.03)%,P〈0.01。(4)左心房内径〈40mm患者的转复率(75.00%)与内径≥40mm患者的转复率(50.00%)差异无统计学意义(P〉0.05)。结论静脉注射伊布利特在持续性房颤射频消融术中应用疗效迅速,对消融后心房扑动转复率更高。转律的成功率与术中标测瘢痕区面积所占比例相关。 Objective The aim of this study was to investigate the efficiency and safety of ibutilide for eardioversion of persistent atrial fibrillation (AF) during radiofrequency ablation. Methods Eighteen patients (16 males) with persistent atrial fibrillation were enrolled in this study. All patients underwent circumferential pulmonary vein ablation guided by a Carto three-dimensional mapping system. In addition, linear ablation at the top of the left atrium and the isthmus of mitral valves and complex fractionated atrial electrogram (CAFE) ablation were performed. All patients were still in either atrial fibrillation or atrial flutter after ablation, the patients were treated with 1 mg intravenous ibutilide injection within 10 minutes after unsuccessful ablation. Intravenous injection was stopped in case of sinus rhythm (SR) restoration or occurrence of severe adverse reactions such as ventrieular taehycardia. Cardioversion rate within 30 min and adverse reactions within 4 h were observed. Patients were divided into either conversion group or non- conversion group according to whether AF was converted to sinus rhythm within 30 minutes after injection. Results Eleven patients (61.11%) converted to SR after ibutilide injection. There were no significant differences in gender, age, body mass index, left atrium and left ventricular function between conversion group and non-conversion groups. The average conversion time was ( 13.80 ±7.64 ) min, left atrium scar area ratio was significantly larger in non-conversion group ( 12. 40 ± 11.03 ) % than in conversion group (5.12±3.83 )% ,P 〈 0. 05. Ibutilide significantly prolonged the average wavelength of the AF wave ( 171.8±29. 5 ) ms vs. (242. 0 ± 40. 0) ms at baseline, P 〈 0. 01. The QT interval at 30 min after ibutilide injection (0. 39 ±0. 21)s was significantly longer than before injection (0. 51±0. 08) s, P 〈0. 05. There was no serious arrhythmias or other adverse reactions post ibutilide injection. Conclusions Ibutilide is highly effective and safe agent for cardioversion in patients underwent unsuccessful ablation. Left atrium scar area ratio is an important determinant for the conversion rate in this cohort.
出处 《中华心血管病杂志》 CAS CSCD 北大核心 2011年第11期1029-1032,共4页 Chinese Journal of Cardiology
关键词 伊布利特 心房颤动 导管消融术 Ibutilide Atrial fibrillation Catheter ablation
  • 相关文献

参考文献16

  • 1Singh SM, D' Avila A, Kim SJ, et al. Intraprocedural use of ibutilide to organize and guide ablation of complex fractionated atrial elcctrograms : preliminary assessment of a modified stepwise approach to ablation of persistent atrial fibrillation. J Cardiovasc Electrophysiol,2010, 21 : 608-616.
  • 2Schwartz RA, Iaagberg JJ. Atrial electrophysiological effects of ibutilide infusion in humans. PACE .2000.23:832-836.
  • 3张海澄,郭继鸿,方全,郑亚安,孙跃民,朱文青,万征,郭静萱,葛均波,韩少梅.静脉注射伊布利特与普罗帕酮转复心房颤动和扑动的多中心研究[J].中华医学杂志,2005,85(12):798-801. 被引量:43
  • 4孙健玲,郭继鸿,张楠,张海澄,张萍.伊布利特治疗心房扑动的疗效观察[J].中华心律失常学杂志,2005,9(4):302-303. 被引量:4
  • 5Kafkas NV, Patsilinakos SP, Mertzanos GA, et al. Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter. International J Cardiol,2007 ,118 :321-325.
  • 6杨敏,廖德宁,张家友,顾兴建,杜荣增,赵伟,赵学,吴宗贵.伊布利特转复心房颤动/心房扑动的临床观察[J].中华心律失常学杂志,2005,9(4):291-294. 被引量:16
  • 7Mazzocca G, Corbucci G, Venturini E, et al. Is pretreatment with ibutilide useful for atrial fibrillation cardioversion when combined with biphasie shock? J Cardiovase Med (Hagerstown),2006,7: 124-128.
  • 8Zarkin GA, Bala MV, Calingaert B, et al. The cost-effectiveness of ibutilide versus electrical cardioversion in the conversion of atrial fibrillation and flutter to normal rhythm. Am J Manag Care, 1997, 3 : 1387-1394.
  • 9Oral H, Knight BP, Tada H, et al. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. Circulation, 2002, 105 : 1077-1081.
  • 10Willems S, Klemm H, Rostock T, et al. Substrate modification combined with pulmonary vein isolation improves outcome of catheter ablation in patients with persistent atrial fibrillation: a prospective randomized comparison. Eur Heart J, 2006,27:2871- 2878.

二级参考文献37

  • 1马虹,陈小林.新Ⅲ类抗心律失常药物治疗心房颤动[J].中华心律失常学杂志,2006,10(1):70-73. 被引量:16
  • 2Antonicelli R, Testarmata P, Recanatini A. Zbvtilide in rapid conversion of atrial flutter in octogenarians[J]. Drugs Aging,2002, 19:787-791.
  • 3Volqman AS, Carberry PA, Stambler B, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coil Cardiol, 1998,31 (6) :1414-1419.
  • 4Vos MA, Golitsyn SR, Stangl K, et al. Superiority of ibutilide ( a new class Ⅲ agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The ibutilide/sotalol comparator study group. Heart, 1998, 79:568-575.
  • 5Bernard EO, Schmid ER, Schmidlin D, et al. Ibutilide versus amiodarone in atrial fibrillation: a double-blinded, randomized study. Crit Care Med,2003,31:1031-1034.
  • 6Oral H, Chugh A, Good E, et al. A tailored approach to catheter ablation of paroxysmal atrial fibrillation. Circulation, 2006, 113 (15): 1824-1831.
  • 7Pappone C, Santinelli V. Atrial fibrillation ablation : state of the art. Am J Cardiol,2005 ,96(12) :59-64.
  • 8Oral H, Knight BP,Tada H, et al. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. Circulation, 2002, 105 ( 9 ) : 1077-1081.
  • 9Willems S, Klemm H, Rostock T, et al. Substrate modification combined with pulmonary vein isolation improves outcome of catheter ablation in patients with persistent atrial fibrillation:a prospective randomized comparison. Eur Heart J ,2006,27 ( 23 ) :2871-2878.
  • 10Botkin SB, Dhanekula LS, Olshansky B. Outpatient cardioversion of atrial arrhythmias: efficacy, safety, and costs. Am Heart J, 2003,145 : 233 -238.

共引文献55

同被引文献83

  • 1黄冬,李京波,魏盟.伊布利特抗心律失常作用的电生理学基础及其临床意义[J].中国新药与临床杂志,2005,24(11):910-912. 被引量:8
  • 2周筠,臧伟进,杜克莘,于晓江,崔长琮.胺碘酮对犬左心室M细胞动作电位和心室跨壁复极离散度的影响[J].心脏杂志,2006,18(2):155-158. 被引量:2
  • 3Vos MA, Golitsyn SR, Stangl K, eta/. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol comparator study group[J]. Heart, 1998, 79(6):568-575.
  • 4Bernard EO, Sehmid ER, Schmidlin D, et M. Ibutilide versus amiodarone in atrial fibrillation: a double-blinded, rando- mized study[J]. Crit Care Med, 2003, 31(4):1031-1034.
  • 5Gowda RM, Khan IA, Wilbur SL, et al. Torsade de pointes: the clinical considerations[J]. Int J Cardiol, 2004, 96(1):1-6.
  • 6Liu T, Brown BS, Wu Y, eta/. Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias [J]. Heart Rhythm, 2006, 3(8):948-956.
  • 7Watanabe N, Kobayashi Y, Tanno K, et a/. Transmural dispersion of repolarization and ventricular tachyarrhythmias [J]. J Electrocardiol, 2004, 37(3):191-200.
  • 8Glatter K, Yang Y, Chatterjee K, et al. Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy[J]. Circulation, 2001, 103(2):253-257.
  • 9Fuster V,Ryden LE,Cannom DS,et al.ACC/AHA/ESC 2006guidelines for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines(Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.Europace,2006,48:651-745.
  • 10Fuster V,Ryden LE,Cannom DS,et al.2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.J Am Coll Cardiol,2011,57:101-198.

引证文献7

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部